Managing Director Stephanie Simon of Winslow Capital Management says Celgene Corporation (CELG) has been a spectacular growth story over the last couple of years and is continuing to be an attractive investment.
“Celgene’s major drug is REVLIMID, and that has been on the market, and that company is growing its top line very dramatically currently. They are also in the process of expanding their business, and we like the pipeline there a great deal,” Simon says.
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Simon says she still likes the growth profile for REVLIMID. And, as the company expands its pipeline from here, she expects further growth.
“So it is the growth prospects and the strength of the company that really is attracting us in terms of Celgene,” Simon says.
Celgene Corporation (CELG) Diversifies Revenue Stream, Sees $1.5 Billion Opportunity in Cancer Drug Abraxane
April 29, 2013
Celgene Corporation (CELG) Looking at 20% Earnings Growth for 2016
February 03, 2016
Celgene Corporation (NASDAQ:CELG) Builds on Success of REVLIMID
April 11, 2016
Medtronic (MDT) Slowly Moves Away from Mature Markets and Grows Its Pipeline
March 19, 2013
New Oriental Education & Tech Grp (ADR) (NYSE:EDU) to Sustain Year-on-Year Margin Improvement and Solid Top-Line Growth
September 04, 2013
